Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India.

Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or ...

With this launch, India has become the third country in the world, after China and the US, to receive access to this ...

Dr Reddy's Laboratories has launched toripalimab, an immune oncology drug for adults with recurrent or metastatic ...

Dr. Reddy's Laboratories Ltd. (RDY) said that it has launched Toripalimab in India, the first and only immuno-oncology drug approved ...

Statin use during concurrent chemoradiotherapy (CCRT) for advanced nasopharyngeal cancer (NPC) is associated with a 52% ...

In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for ...

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab ...

News on Telangana Today, Metastatic nasopharyngeal carcinoma (RM-NPC) latest news, Metastatic nasopharyngeal carcinoma (RM-NPC) news, | Telangana Today ...

In 2023, Dr Reddy's signed a licensing and commercialization agreement with Shanghai Junshi Biosciences for Toripalimab which ...

Dr. Reddy’s Laboratories has launched Toripalimab, a New Biological Entity (NBE) in the domestic market. “The launch of ...

Dr. Reddy's Laboratories has announced the launch of Toripalimab in India. This drug is designed to treat adults suffering ...